DK0734729T4 - Anvendelse af en CGRP-antagonist til behandling af hudrödme af neurogen oprindelse og den opnåede sammensætning - Google Patents

Anvendelse af en CGRP-antagonist til behandling af hudrödme af neurogen oprindelse og den opnåede sammensætning

Info

Publication number
DK0734729T4
DK0734729T4 DK96400457T DK96400457T DK0734729T4 DK 0734729 T4 DK0734729 T4 DK 0734729T4 DK 96400457 T DK96400457 T DK 96400457T DK 96400457 T DK96400457 T DK 96400457T DK 0734729 T4 DK0734729 T4 DK 0734729T4
Authority
DK
Denmark
Prior art keywords
composition obtained
cgrp antagonist
treat skin
skin redness
neurogenic origin
Prior art date
Application number
DK96400457T
Other languages
English (en)
Other versions
DK0734729T3 (da
Inventor
Lacharriere Olivier De
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0734729(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Application granted granted Critical
Publication of DK0734729T3 publication Critical patent/DK0734729T3/da
Publication of DK0734729T4 publication Critical patent/DK0734729T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK96400457T 1995-03-28 1996-03-04 Anvendelse af en CGRP-antagonist til behandling af hudrödme af neurogen oprindelse og den opnåede sammensætning DK0734729T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503628A FR2732221B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue

Publications (2)

Publication Number Publication Date
DK0734729T3 DK0734729T3 (da) 1999-04-19
DK0734729T4 true DK0734729T4 (da) 2004-10-25

Family

ID=9477498

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96400457T DK0734729T4 (da) 1995-03-28 1996-03-04 Anvendelse af en CGRP-antagonist til behandling af hudrödme af neurogen oprindelse og den opnåede sammensætning

Country Status (15)

Country Link
US (2) US5932215A (da)
EP (1) EP0734729B2 (da)
JP (1) JPH08268874A (da)
AR (1) AR002974A1 (da)
AT (1) ATE168011T1 (da)
BR (1) BR9601478A (da)
CA (1) CA2172777C (da)
DE (1) DE69600399T3 (da)
DK (1) DK0734729T4 (da)
ES (1) ES2121461T5 (da)
FR (1) FR2732221B1 (da)
HU (1) HUP9600765A3 (da)
MX (1) MX9601150A (da)
PL (1) PL313515A1 (da)
RU (1) RU2152798C1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
FR2768621B1 (fr) * 1997-09-22 2000-04-07 Oreal Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
CA2446356C (en) * 2001-05-09 2012-07-10 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
PL375536A1 (en) 2002-08-12 2005-11-28 Birkir Sveinsson Use of cgrp antagonist compounds for treatment of psoriasis
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
BRPI0618705B8 (pt) 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
CA2716424C (en) 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
WO2009152372A1 (en) * 2008-06-11 2009-12-17 Biochemics, Inc. Control of blood vessel physiology to treat skin disorders
WO2010030821A2 (en) 2008-09-10 2010-03-18 Biochemics, Inc. Ibuprofen for topical administration
CA2702604C (en) 2008-09-22 2013-12-03 Biochemics, Inc. Transdermal drug delivery using an osmolyte and vasoactive agent
US9278233B2 (en) * 2008-12-04 2016-03-08 Biochemics, Inc. Methods and compositions for tattoo removal
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
RU2535074C2 (ru) 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
KR20130018739A (ko) * 2010-03-03 2013-02-25 네오큐티스 에스아 항균 펩티드 격리 화합물을 사용한 피부 질환 및 장애의 치료를 위한 조성물 및 방법
KR20170018974A (ko) 2010-03-26 2017-02-20 갈데르마 리써어치 앤드 디벨로프먼트 홍반의 유효하고 안전한 치료를 위한 개선된 방법 및 조성물
CA2836800A1 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
LT2710039T (lt) 2011-05-20 2019-04-25 Alderbio Holdings Llc Anti-cgrp kompozicijos ir jų panaudojimas
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
US20180185360A1 (en) * 2015-06-29 2018-07-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
MX2019003337A (es) 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento para migraña refractaria.
US11433119B2 (en) 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders
AU2020206241A1 (en) 2019-01-08 2021-08-26 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
TW263498B (da) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
PT751789E (pt) * 1994-03-21 2002-04-29 Aase Brown Thomsen Gel para o tratamento de doencas da pele e para desinfeccao da pele
DE69529043T2 (de) * 1994-09-30 2003-05-08 L'oreal S.A., Paris Verwendung von einem Agonisten eines mit einem Chloridkanal assozierten Rezeptors zur Behandlung von Hautfalten
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
FR2728169A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728265A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
PL313515A1 (en) 1996-09-30
MX9601150A (es) 1997-02-28
FR2732221B1 (fr) 1997-04-25
AR002974A1 (es) 1998-05-27
EP0734729B2 (fr) 2004-09-29
HU9600765D0 (en) 1996-05-28
BR9601478A (pt) 1998-06-02
ES2121461T3 (es) 1998-11-16
EP0734729B1 (fr) 1998-07-08
DE69600399T2 (de) 1998-10-29
US5932215A (en) 1999-08-03
HUP9600765A2 (en) 1997-06-30
ATE168011T1 (de) 1998-07-15
EP0734729A1 (fr) 1996-10-02
US6509014B1 (en) 2003-01-21
DE69600399T3 (de) 2005-07-14
DE69600399D1 (de) 1998-08-13
FR2732221A1 (fr) 1996-10-04
ES2121461T5 (es) 2005-05-01
CA2172777A1 (fr) 1996-09-29
HUP9600765A3 (en) 1998-04-28
JPH08268874A (ja) 1996-10-15
RU2152798C1 (ru) 2000-07-20
CA2172777C (fr) 2007-07-24
DK0734729T3 (da) 1999-04-19

Similar Documents

Publication Publication Date Title
DK0734729T4 (da) Anvendelse af en CGRP-antagonist til behandling af hudrödme af neurogen oprindelse og den opnåede sammensætning
DK0723774T3 (da) Anvendelse af en antagonist for CGRP i en kosmetisk, farmaceutisk eller dermatologisk sammensætning og den opnåede sammensæ
PT1123255E (pt) Coluna de bolhas e sua utilizacao
KR970706257A (ko) 치환된 피리딘의 구충제 및 살진균제로서의 용도(use of substituted pyridines as pest-control agents and fungicides)
NO954239L (no) Heterocykliske forbindelser og deres fremstilling og anvendelse
FI932517A0 (fi) Antagonister av angiotensin II
FI932695A0 (fi) Angiotensin I kymas-inhibitorer inklusive humant hjaertkymas
NO983187L (no) Substituerte aza- og diazacykloheptan og -cyklooktan-forbindelse og deres anvendelse
NO20015274D0 (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
LV11465A (lv) Heterocikliski amidini panemiens to iegusanai un pielietojums
EE200000093A (et) Agrekanaasi ja maatriksmetalloproteinaaside uudsed inhibiitorid artriidi käitlemiseks
DK0722722T3 (da) Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse
FR2779638B1 (fr) Composition cosmetique contenant un polysaccharide et un terpolymere acrylique et utilisation de cette composition pour le traitement des matieres keratiniques
DE69801878D1 (de) Verwendung von Oxamatderivaten als Depigmentierungsmittel
FI973211A (fi) Ihmisen leukosyyttielastaasin inhibiittoreina hyödylliset proliinijohdannaiset
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DK0898566T3 (da) Substituerede benzylaminer og anvendelse deraf til behandling af depression
DK0734730T3 (da) Anvendelse af en CGRP-antagonist til behandling af øjen- eller øjenlågskløe og -dysæstesier
FR2732220B1 (fr) Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
PT826679E (pt) Compostos de naftilo intermediarios composicoes e metodos de utilizacao
BR9711842A (pt) Derivados de n-(benzotiazol-2-il) piperidina-1-etanamina sua prepara-Æo e sua aplica-Æo em terap-utica
MA21480A1 (fr) Utilisation d'inhibiteurs de l'enzyme de conversion de l'angiotensine .
IS4232A (is) Súbstitúerað bensimidasól, aðferðir við framleiðslu þess og lyfjafræðileg notkun
KR920007957U (ko) 비탈면 수로 겸용 보호블럭
DK0917827T3 (da) Fremgangsmåde til fremstilling af flæsk og den særlige anvendelse af det ifølge denne fremgangsmåde fremstillede flæsk